Positive Late-Breaking Data For Incyte's First-In-Class Mutcalr-Targeted Therapy Inca033989 In Essential Thrombocythemia Presented At Eha2025
June 15 (Reuters) - Incyte Corp INCY.O:
POSITIVE LATE-BREAKING DATA FOR INCYTE’S FIRST-IN-CLASS MUTCALR-TARGETED THERAPY INCA033989 IN ESSENTIAL THROMBOCYTHEMIA PRESENTED AT EHA2025
INCYTE CORP - INCA033989 SHOWS POTENTIAL TO MODIFY DISEASE BY TARGETING MUTCALR CELLS
INCYTE CORP - 86% OF HIGH-RISK ET PATIENTS ACHIEVED HEMATOLOGIC RESPONSE WITH INCA033989
INCYTE CORP - 89% OF PATIENTS SHOWED REDUCTION IN MUTCALR VARIANT ALLELE FREQUENCY
INCYTE CORP - ONLY ONE PATIENT DISCONTINUED TREATMENT DUE TO TEAES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Tradingkey








